Trastuzumab Injection About

Transtuzumab:-

Transtuzumab is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high risk feature.
Trastuzumab is approved to be used alone or with other drugs to treat:

Adenocarcinoma of the stomach or gastroesophageal junction. It is used for HER2 positive (HER2+) disease that has metastasized (spread to other parts of the body) in patients who have not already been treated for metastatic cancer.

Breast cancer that is HER2+. It is used in patients whose disease has not gotten better with other chemotherapy.
Trastuzumab usually is administered intravenously with an initial dose of 4 mg per kilogram of body weight followed by a weekly dose of 2 mg per kilogram of body weight.

Mechanism of Action

Trastuzumab specifically targets the HER2/neu receptor on cancer cells, inhibiting their growth and survival. By binding to these receptors, the drug helps enhance the immune response against tumor cells, contributing to effective targeted therapy in oncology.


Reconstitution and Administration

The lyophilized powder must be reconstituted with the supplied sterile water for injection before use. Following reconstitution, the solution should be gently swirled, not shaken, to ensure dissolution. The medication must be used within 24 hours and is administered through intravenous infusion under healthcare supervision.


Storage and Stability

Trastuzumab Injection should be stored in a refrigerator at 2C to 8C and must not be frozen. Once reconstituted, it should be kept at the same temperature and used within 24 hours to ensure product efficacy and safety.